Global E-Health Forum: Designing Personalized Healthcare

11 - 13 October 2011, Hamburg, Germany.
Dr. Eric M. Liederman (Director of Medical Informatics, The Permanente Medical Group, U.S.A.) has confirmed his keynote at this year's Global E-Health Forum. He will present "Balancing Privacy Protection with Patient Care".

Healthcare organizations are under increasing regulatory pressure to improve the quality and safety of care and to protect patient privacy. Electronic Health Records (EHR) provide a vehicle to improve care, however concerns over protecting the system against privacy violations are a significant challenge. Dr. Eric Liederman will discuss how to achieve a balance between protecting privacy and security, and fostering high quality patient care.

Learn how Kaiser Permanente's "trust, but hold accountable" approach using forensic mining of its EHR audit databases, resulted in a > 90% reduction in privacy violations over several weeks. Learn how deterrence methods have also helped clinicians and staff avoid giving in to career-ending temptation.

Canada is Partner Country
Mr. Peter M. Boehm, Ambassador of Canada in Germany is pleased to endorse the Global E-Health Forum in Hamburg. He states: "Developing successful e-health solutions requires combining knowledge and technology in several key areas, including: enabling electronic communications infrastructure; providing remote communities in Canada with access to clinical and non-clinical healthcare professionals through the use of advanced information communications technologies; improving health information systems to support service delivery including virtual health libraries; and upholding the health privacy of patients through high standards of information management and exchange." For full text, please see http://www.global-ehealth-forum.com/canada/.

Transforming healthcare in Canada through e-health, the challenges facing the health system in Canada and the role of information and information technology within a reformed health system - these are the topics Richard C. Alvarez, President and Chief Executive Officer, Canada Health Infoway, will address in his keynote.

Program
The first two conference days at the Hamburg Chamber of Commerce will feature more speakers from all over the globe. Their strategy presentations and case studies will be complemented by discussion forums, workshops and an exhibition of solution providers. The official reception for the conference delegates will take place in the U.S. Consulate General ("the little White House at the lake Alster") on October 11. The third day is dedicated to various breakout sessions and guided tours at different locations (among others hospitals) targeting the individual information needs of special interest groups.

Registration
Register by August 30 for a conference fee of Euro 599 incl. VAT. The fee includes the admission to all conference sessions, lunches, coffee breaks and the evening reception on October 11, 2011.

For further information, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...